Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Total Debt (2016 - 2024)

Historic Total Debt for Regen BioPharma (RGBP) over the last 9 years, with Q2 2024 value amounting to $800149.0.

  • Regen BioPharma's Total Debt rose 1.86% to $800149.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $800149.0, marking a year-over-year increase of 1.86%. This contributed to the annual value of $949614.0 for FY2023, which is 2859.35% up from last year.
  • Per Regen BioPharma's latest filing, its Total Debt stood at $800149.0 for Q2 2024, which was up 1.86% from $943685.0 recorded in Q1 2024.
  • In the past 5 years, Regen BioPharma's Total Debt registered a high of $66.8 million during Q1 2022, and its lowest value of $266667.0 during Q3 2020.
  • For the 5-year period, Regen BioPharma's Total Debt averaged around $4.4 million, with its median value being $800000.0 (2020).
  • In the last 5 years, Regen BioPharma's Total Debt skyrocketed by 1897920.86% in 2022 and then tumbled by 9880.2% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Total Debt stood at $350000.0 in 2020, then soared by 133.24% to $816327.0 in 2021, then grew by 0.51% to $820513.0 in 2022, then grew by 16.27% to $953981.0 in 2023, then decreased by 16.13% to $800149.0 in 2024.
  • Its last three reported values are $800149.0 in Q2 2024, $943685.0 for Q1 2024, and $953981.0 during Q4 2023.